{"id":32178,"date":"2025-04-22T14:27:10","date_gmt":"2025-04-22T06:27:10","guid":{"rendered":"https:\/\/flcube.com\/?p=32178"},"modified":"2025-04-22T14:27:11","modified_gmt":"2025-04-22T06:27:11","slug":"novo-nordisks-wegovy-gets-nmpa-label-update-for-cardiovascular-risk-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32178","title":{"rendered":"Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction"},"content":{"rendered":"\n

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE: NVO<\/a>) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.<\/p>\n\n\n\n

SELECT Study Results<\/strong>
The SELECT study, a large-scale clinical trial, showed significant cardiovascular benefits of Wegovy. In adult patients with overweight or obesity and confirmed cardiovascular disease, the drug reduced the risk of MACE, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This approval underscores Wegovy’s role in addressing both weight management and cardiovascular health.<\/p>\n\n\n\n

Global Recognition and Health Benefits<\/strong>
Wegovy, the world’s first weekly GLP-1 receptor agonist (GLP-1RA) for long-term weight management, is approved in over 10 countries and regions. The STEP series and SELECT studies, involving approximately 25,000 participants, validated Wegovy’s efficacy in achieving and sustaining weight loss. The drug has shown an average weight loss of about 17%, with one-third of patients experiencing over 20% weight loss lasting at least two years. Additionally, Wegovy offers health benefits beyond weight loss, such as reducing waist circumference, visceral fat, improving blood lipids, and reversing prediabetes.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:…<\/p>\n","protected":false},"author":1,"featured_media":32179,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[148,860,86],"class_list":["post-32178","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"\nNovo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32178\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction\" \/>\n<meta property=\"og:description\" content=\"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32178\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T06:27:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-22T06:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction\",\"datePublished\":\"2025-04-22T06:27:10+00:00\",\"dateModified\":\"2025-04-22T06:27:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2205.webp\",\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32178#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32178\",\"name\":\"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2205.webp\",\"datePublished\":\"2025-04-22T06:27:10+00:00\",\"dateModified\":\"2025-04-22T06:27:11+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32178\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32178#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction - Insight, China's Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32178","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction","og_description":"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.","og_url":"https:\/\/flcube.com\/?p=32178","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-22T06:27:10+00:00","article_modified_time":"2025-04-22T06:27:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32178#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32178"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction","datePublished":"2025-04-22T06:27:10+00:00","dateModified":"2025-04-22T06:27:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32178"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32178#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","keywords":["Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32178#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32178","url":"https:\/\/flcube.com\/?p=32178","name":"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32178#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32178#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","datePublished":"2025-04-22T06:27:10+00:00","dateModified":"2025-04-22T06:27:11+00:00","description":"China's National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32178#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32178"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32178#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","width":1080,"height":608,"caption":"Novo Nordisk's Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32178#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32178"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32178\/revisions"}],"predecessor-version":[{"id":32180,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32178\/revisions\/32180"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32179"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}